Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy?

Core Viewpoint - The market anticipates Arcutis Biotherapeutics, Inc. (ARQT) will report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus EPS estimate for Arcutis is $0.03 per share, reflecting a year-over-year increase of +133.3% [3]. - Expected revenues are $115.71 million, which is a 62.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Arcutis is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -160.00%, suggesting a bearish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Arcutis was expected to post a loss of $0.1 per share but instead reported earnings of $0.06, resulting in a surprise of +160.00% [13]. - Over the last four quarters, Arcutis has beaten consensus EPS estimates four times [14]. Investment Considerations - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 4 indicates that Arcutis may not be a compelling candidate for an earnings surprise [12][17]. - Investors are advised to consider other factors beyond earnings results when making investment decisions regarding Arcutis [15][17].